| Bioactivity | Amcasertib (BBI503) is an orally active and small-molecule multi-kinase inhibitor. Amcasertib exhibits inhibitory activity against the NANOG and CD133 expression and cell viability in PC-9/GR cells. As an orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity, it is currently being studied in phase I clinical trials in a number of cancers. | ||||||||||||
| Invitro | Amcasertib (0-1μM; 48h) inhibits the NANOG and CD133 expression in PC-9/GR cells. Amcasertib also significantly suppresses the growth of PC-9/GR cells in a dose-dependent manner[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Amcasertib | ||||||||||||
| CAS | 1129403-56-0 | ||||||||||||
| Formula | C31H33N5O2S | ||||||||||||
| Molar Mass | 539.69 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Jia Z, et al. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells. Cell Death Dis. 2020;11(8):670 |
Amcasertib
CAS: 1129403-56-0 F: C31H33N5O2S W: 539.69
Amcasertib (BBI503) is an orally active and small-molecule multi-kinase inhibitor. Amcasertib exhibits inhibitory activi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.